Related Experiment Video
Updated: Oct 13, 2025
08:42
Application of a C. elegans Dopamine Neuron Degeneration Assay for the Validation of Potential Parkinson's Disease Genes
Published on: July 18, 2008
16.2K
Navigating the open sea of commercial genetic testing in Parkinson's disease
1Genomic Medicine Institute, Lerner Research Institute, R4-006, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH, 44195, USA.
Parkinsonism & Related Disorders
|November 14, 2021
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
824
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
824
01:24Parkinson's Disease: Treatment
441
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
441